Introduction {#sec1-1}
============

Acute pancreatitis is an acute inflammatory disorder of the pancreas. Clinically, it can potentially lead to severe morbidity and mortality. In Appelros and Borgström study in Sweden, the annual incidence of the first attack of acute pancreatitis was 23.4 cases per 100,000 population, and the annual mortality rate for acute pancreatitis was 1.3 cases per 100,000 population.\[[@ref1]\]

Although many causes of acute pancreatitis have been well-established,\[[@ref1][@ref2][@ref3]\] drug-induced pancreatitis has also been discovered.\[[@ref4]\] To date, five cases of acute pancreatitis were reported to be associated with the use of methimazole.\[[@ref5][@ref6][@ref7][@ref8][@ref9]\] Methimazole is a drug frequently used to treat hyperthyroidism and Graves' disease. Its adverse effects mainly include rash, pruritus, arthralgia, and leucopenia,\[[@ref10]\] but acute pancreatitis is rarely mentioned.

Case reports are frequently used to detect adverse drug effects. There is still a lack of formal epidemiological studies to support the relationship between the use of methimazole and risk of acute pancreatitis. Due to severe morbidity and mortality associated with acute pancreatitis, it is necessary to estimate the risk of acute pancreatitis in users of methimazole. We therefore conducted a population-based case--control study to investigate whether there is an association between the use of methimazole and risk of acute pancreatitis.

Methods {#sec1-2}
=======
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### Design and Data Source {#sec3-1}

A population-based case--control study was conducted to analyze the database of the Taiwan National Health Insurance Program. This insurance program launched in March 1995 and has covered 99% of the entire population of 23 million people living in Taiwan.\[[@ref11]\] The details of the insurance program were well-addressed in previous studies.\[[@ref2][@ref12][@ref13]\] This study was approved by the Ethics Review Board of China Medical University and Hospital in Taiwan (CMUH-104-REC2-115).

### Cases and Controls {#sec3-2}

Individuals aged 20--84 years with a first attack of acute pancreatitis in 1998--2011 were identified as the cases, according to International Classification of Diseases 9^th^ Revision Clinical Modification (ICD-9 code 577.0). The index date for each case was defined as the date of diagnosing acute pancreatitis. The controls were aged 20--84 years randomly selected from those without acute pancreatitis in a ratio of 1:4 (cases vs. controls). Both cases and controls were matched for sex, age (per 5 years), and the year of diagnosing acute pancreatitis. Individuals who had ever used carbimazole or propylthiouracil were excluded from this study. Individuals with complete thyroidectomy, thyroid cancer, chronic pancreatitis, or pancreatic cancer before the index date were also excluded from this study.

### Definition of Methimazole Exposure {#sec3-3}

To investigate the association between the use of methimazole and risk of acute pancreatitis, history of methimazole prescription before the index date was examined. Individuals who never had a methimazole prescription were defined as never use of methimazole. Individuals who ever had a methimazole prescription were defined as ever use of methimazole.

### Potential Confounding Factors {#sec3-4}

Other medical conditions potentially associated with acute pancreatitis were included as covariables such as alcohol-related disease, biliary stone, and cardiovascular disease including coronary artery disease, heart failure, cerebrovascular disease and peripheral atherosclerosis, chronic obstructive pulmonary disease, diabetes mellitus, hepatitis B, hepatitis C, as well as hypertriglyceridemia. Based on ICD-9 codes, the diagnosis accuracy of medical conditions included has been examined in previous studies.\[[@ref14][@ref15][@ref16][@ref17]\]

### Statistical Analysis {#sec3-5}

Initially, the Chi-square test was used to compare the differences between the cases and controls for demographic profiles, methimazole use, and other medical conditions. Next, all variables were included in the univariable unconditional logistic regression model. Finally, only those significant variables were further included in the multivariable unconditional logistic regression model to examine the odds ratio (OR) and 95% confidence interval (CI) for risk of acute pancreatitis associated with methimazole use and other medical conditions. The *P* \< 0.05 was considered statistically significant (SAS software version 9.2, SAS Institute Inc., Cary, North Carolina, USA).

Results {#sec1-3}
=======
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### Characteristics of the Study Population {#sec3-6}

A total of 5764 cases with acute pancreatitis and 23,056 controls were included in the study. When compared with the controls, histories of alcohol-related disease, biliary stone, cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, hepatitis B, hepatitis C, and hypertriglyceridemia were more prevalent among the cases with acute pancreatitis (Chi-square test, P\<0.001 for all) \[[Table 1](#T1){ref-type="table"}\]. There was no significant difference in ever use of methimazole between the cases and controls (*P* = 0.32). The mean ages (standard deviation) were 51.89 (16.58) years in the cases and 52.35 (16.41) years in the controls (*P* = 0.06 for *t*-test).

###### 

Characteristics of cases with acute pancreatitis and controls
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### Odds Ratio of Acute Pancreatitis Associated with Use of Methimazole and Other Medical Conditions {#sec3-7}

After adjustment for confounding factors, the OR of acute pancreatitis was 0.91 in individuals with ever use of methimazole, when compared with individuals with never use of methimazole (95% CI, 0.60--1.38). Unlike methimazole use, alcohol-related disease, biliary stone, cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, hepatitis B, hepatitis C, and hypertriglyceridemia were factors significantly associated with acute pancreatitis \[[Table 2](#T2){ref-type="table"}\].

###### 

Crude and adjusted odds ratio and 95% confidence interval of acute pancreatitis associated with methimazole use and comorbidities in study individuals
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Discussion {#sec1-4}
==========

In this population-based case--control study, we did not notice any increased odds of acute pancreatitis in users of methimazole. In further analysis, methimazole users were divided into two subgroups: Current use and past use of methimazole. No significant association was found between current use or past use of methimazole and acute pancreatitis (data not shown). To date, only five cases of acute pancreatitis were reported to be associated with use of methimazole, including four cases having a definite causal relationship after rechallenge test\[[@ref5][@ref6][@ref8][@ref9]\] and one case only with probable association without rechallenge test.\[[@ref7]\] There appears to be a discrepancy between case reports and this present population-based data on the association between use of methimazole and risk of acute pancreatitis. Therefore, we cannot confirm the hypothesis of methimazole-associated acute pancreatitis previously raised in case reports.

Some important issues need to be considered in the interpretation of our data. First, although methimazole is no longer used in some countries and so its relevance is low, methimazole is a drug frequently used to treat hyperthyroidism and Graves' disease worldwide. Before analysis, nobody knows whether individuals with acute pancreatitis have a higher proportion of ever use of methimazole. Among the cases with acute pancreatitis in this study, only 39 individuals (0.68%) had ever used methimazole. Among the controls, only 130 individuals (0.56%) had ever used methimazole. There was no significant difference in ever use of methimazole between the cases and controls. Moreover, it is relatively difficult to detect any association in this case--control study involving only a small number of individuals using methimazole. Further studies with more individuals using methimazole are needed to clarify this association. Second, due to the intrinsic limitation of this database, the exact causes of acute pancreatitis in this study were not registered. Therefore, we did not make sure whether or not a few cases could be potentially associated with use of methimazole. Third, we hope to show the original differences of medical conditions between the cases and controls. Both cases and controls were only matched for sex and age, but not for medical conditions. That is why the prevalent rates of acute pancreatitis-related factors were higher in the cases than the controls [Table 1](#T1){ref-type="table"}. Fourth, causal-effect assessment is a relatively critical and complex field in pharmacovigilance. Because an association between methimazole use and acute pancreatitis cannot be detected through our conventional statistical methodology, spontaneous adverse drug reaction reports remain to be important to dedicate pharmacovigilance databases.

Conclusions {#sec1-5}
===========

We cannot detect an association between methimazole use and acute pancreatitis on the basis of systematic analysis. Therefore, we cannot confirm the hypothesis of methimazole-associated acute pancreatitis previously raised in case reports.
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